机译:黄原氧化酶抑制剂Topiroxostat在减少血管紧张素II型1型接受者表达下的重新调试作用
Division of Nephrology and Hypertension Department of Internal Medicine St. Marianna University;
Division of Nephrology and Hypertension Department of Internal Medicine St. Marianna University;
Division of Nephrology and Hypertension Department of Internal Medicine St. Marianna University;
Biopharmaceutical Study Group Pharmaceutical Research Laboratories Sanwa Kagaku Kenkyusho Company;
Biopharmaceutical Study Group Pharmaceutical Research Laboratories Sanwa Kagaku Kenkyusho Company;
Radioisotope and Chemical Analysis Center Laboratory Management Department Sanwa Kagaku Kenkyusho;
CMIC Holdings Company Limited;
Department of Anatomy St. Marianna University School of Medicine;
Division of Nephrology and Hypertension Department of Internal Medicine St. Marianna University;
Division of Nephrology and Hypertension Department of Internal Medicine St. Marianna University;
JCHO Tokyo Takanawa Hospital;
Division of Nephrology and Hypertension Department of Internal Medicine St. Marianna University;
Topiroxostat; Xanthine oxidoreductase; Xanthine oxidoreductase inhibitor; Renin–angiotensin system; L-FABP; Adenine; Tubulointerstitial damage; Blood pressure;
机译:黄原氧化酶抑制剂Topiroxostat在减少血管紧张素II型1型接受者表达下的重新调试作用
机译:尿酸尿酸药物通过与新药黄嘌呤氧化还原酶抑制剂托泊司他同时治疗降低大鼠血浆尿酸水平
机译:吹笛者Sarmentosum抑制血管紧张素II受体型1,促进血管紧张素II受体型2型表达在培养的内皮细胞中
机译:血管紧张素II 1型受体阻滞剂预处理的血管紧张素II刺激的肾小管细胞的超微结构和力学性能
机译:通过降低NADPH氧化酶表达,通过降低NADPH-1受体激动剂和DPP-4抑制剂减少血管紧张素II诱导的高血压和心肌纤维化
机译:血管紧张素II 2型受体在人肾近端小管细胞中降低转化生长因子-βII型受体的表达和功能
机译:黄嘌呤氧化还原酶抑制剂Topiroxostat对腺嘌呤诱导肾损伤的重新调试作用